A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Umbreen Rozell
Sponsor
Astrazeneca
Unit
Cancer Center Division